Dr. Van Brunt leads the Division of Evidence and Analytics, a team within Health Economics and Outcomes Research (HEOR) focusing on the expansion of Real-World Evidence and Patient-Centered Outcomes. He joined Abbvie in 2014 to head HEOR’s Immunology therapeutic area, where he had strategic and operational oversight of teams providing value evidence in support of Humira and the emerging immunology pipeline.
Prior to joining AbbVie, Dr. Van Brunt formed a pipeline HEOR at Biogen and Lilly, working across the lifecycle and moving HEOR into the earliest stages of drug development. He joined industry from the faculty of the College of Medicine at the University of TN Health Sciences Center, where he still holds an adjunct appointment in the Division of Biostatistics and Epidemiology. Dr. Van Brunt’s PhD is in Psychology, with concentrations in in Behavioral Medicine and research methodology. His clinical residency with the US Air Force culminated in his role as Chief of Psychology Services at US Strategic Command Headquarters, where he first turned his attention from individual to population health. Having published in top-tier medical journals and authoring book chapters and treatment manuals, he has in recent years put down his pen to focus on leading teams to success in finding new applications for real-world evidence and innovative methods to measure value in healthcare.